Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes

Canadian Journal of Physiology and Pharmacology
J Craig HartmanRichard Gorczynski

Abstract

To evaluate potential mechanisms of clinical hepatotoxicity, 4 endothelin receptor antagonists (ERAs) were examined for substrate activity and inhibition of hepatic uptake and efflux transporters in sandwich-cultured human hepatocytes. The 4 transporters studied were sodium-dependent taurocholate cotransporter (NTCP), organic anion transporter (OATP), bile salt export pump (BSEP), and multidrug resistance-associated protein 2 (MRP2). ERA transporter inhibition was examined using the substrates taurocholate (for NTCP and BSEP), [(3)H]estradiol-17beta-D-glucuronide (for OATP), and [2-D-penicillamine, 5-D-penicillamine]enkephalin (for MRP2). ERA substrate activity was evaluated using probe inhibitors ritonavir (OATP and BSEP), bromosulfalein (OATP), erythromycin (P-glycoprotein), probenecid (MRP2 and OATP), and cyclosporin (NTCP). ERAs were tested at 2, 20, and 100 micromol*L-1 for inhibition and at 2 micromol*L-1 as substrates. OATP, NTCP, or BSEP transport activity was not reduced by ambrisentan or darusentan. Bosentan and sitaxsentan attenuated NTCP transport at higher concentrations. Only sitaxsentan decreased OATP transport (52%), and only bosentan reduced BSEP transport (78%). MRP2 transport activity was unaltered. OATP inhi...Continue Reading

References

Mar 22, 2002·The New England Journal of Medicine·Lewis J RubinGerald Simonneau
Jun 6, 2002·British Journal of Clinical Pharmacology·Paul L M van GiersbergenJasper Dingemanse
Nov 25, 2003·American Journal of Respiratory and Critical Care Medicine·Robyn J BarstUNKNOWN STRIDE-1 Study Group
Jul 14, 2004·Chest·Vallerie V McLaughlinUNKNOWN American College of Chest Physicians
Oct 29, 2004·Toxicological Sciences : an Official Journal of the Society of Toxicology·Daniel C KempKim L R Brouwer
Feb 3, 2005·The European Respiratory Journal·V V McLaughlinL J Rubin
Aug 2, 2005·Journal of the American College of Cardiology·Nazzareno GaliéLewis J Rubin
May 16, 2006·Journal of the American College of Cardiology·Robyn J BarstUNKNOWN STRIDE-2 Study Group
Jun 6, 2006·Molecular Pharmaceutics·Giulia GhibelliniKim L R Brouwer
Aug 11, 2006·Chest·Joseph Green
Aug 31, 2006·Cardiovascular Drug Reviews·Hartmut Vatter, Volker Seifert
Nov 18, 2006·American Journal of Respiratory and Critical Care Medicine·Isaiah D WexlerEitan Kerem
Jan 20, 2007·Clinical Pharmacology and Therapeutics·G GhibelliniK L R Brouwer
May 17, 2007·The European Respiratory Journal·M HumbertM M Hoeper
Feb 2, 2008·The European Respiratory Journal·J Dupuis, M M Hoeper
May 29, 2008·Circulation·Nazzareno GalièUNKNOWN Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies
Apr 25, 2009·Journal of Clinical Pharmacology·Duncan B RichardsLinda S Henderson

❮ Previous
Next ❯

Citations

Jun 12, 2013·European Journal of Clinical Pharmacology·Christoph MarkertWalter E Haefeli
Jun 1, 2011·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·James E Frampton
Feb 5, 2014·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Markus P Schneider, Johannes F Mann
May 5, 2011·European Journal of Clinical Pharmacology·Patricia N SidhartaJasper Dingemanse
Feb 2, 2013·Drug Metabolism Reviews·Eva RamboerMathieu Vinken
Aug 7, 2012·Expert Opinion on Drug Safety·Carmine Dario VizzaLewis J Rubin
Nov 26, 2014·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Marie-Camille ChaumaisOlivier Sitbon
Jul 22, 2015·Current Medical Research and Opinion·Andrew J PeacockCarmine Dario Vizza
Mar 20, 2013·Molecular Aspects of Medicine·Sara El-GebaliPascale Anderle
Apr 21, 2017·Therapeutic Advances in Respiratory Disease·Belinda N Rivera-Lebron, Michael G Risbano
Oct 8, 2014·Basic & Clinical Pharmacology & Toxicology·Christoph MarkertWalter Emil Haefeli
May 21, 2014·Clinical Pharmacology and Therapeutics·M RoustitJ-L Cracowski
Apr 4, 2017·Toxicological Sciences : an Official Journal of the Society of Toxicology·Matthew Gibson BurbankAndré Guillouzo
Aug 31, 2012·Therapeutic Advances in Respiratory Disease·Michele D'Alto
May 16, 2018·Archives of Toxicology·Robim M RodriguesMathieu Vinken
May 31, 2018·Journal of Applied Toxicology : JAT·Rhishikesh ThakareYazen Alnouti
Mar 5, 2013·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Cho-Ming LoiDeepak Dalvie
Sep 26, 2013·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Xiao-Mei ZhuangHua Li
Jul 19, 2013·Clinical Pharmacology and Therapeutics·S M MarkovaD L Kroetz
Aug 30, 2017·Expert Opinion on Drug Metabolism & Toxicology·Eve-Irene Lepist, Adrian S Ray
Jul 31, 2019·Applied Microbiology and Biotechnology·Jie WangHaiying Hang
Jun 7, 2013·British Journal of Clinical Pharmacology·Christoph MarkertWalter E Haefeli
Feb 27, 2015·European Journal of Clinical Investigation·Michele CorrealeDonato Lacedonia
Dec 4, 2014·The Journal of Pharmacology and Experimental Therapeutics·J Gerry KennaRichard A Thompson
Sep 1, 2018·European Journal of Drug Metabolism and Pharmacokinetics·Olivier FardelYannick Parmentier
Aug 6, 2021·The Journal of Pharmacology and Experimental Therapeutics·Marlies OortsPieter Annaert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.